Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone

Salvatore Luca Burgio, Vincenza Conteduca, Cecilia Menna, Elisa Carretta, Lorena Rossi, Emanuela Bianchi, Barbara Kopf, Francesca Fabbri, Dino Amadori, Ugo De Giorgi

Research output: Contribution to journalArticlepeer-review


In this retrospective study, we evaluated the chromogranin A (CgA) baseline value as a predictor of clinical outcome in patients with metastatic castration-resistant prostate cancer (CRPC) treated with abiraterone 1000 mg per day, whose disease progressed after docetaxel chemotherapy. In the 48 evaluable patients, serum CgA level was normal when

Original languageEnglish
Pages (from-to)487-493
Number of pages7
JournalEndocrine-Related Cancer
Issue number3
Publication statusPublished - 2014


  • Abiraterone
  • Bone flare
  • Castration-resistant prostate cancer
  • CgA
  • Chromogranin A
  • CRPC
  • PSA

ASJC Scopus subject areas

  • Endocrinology
  • Oncology
  • Cancer Research
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)


Dive into the research topics of 'Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone'. Together they form a unique fingerprint.

Cite this